Mechanism of Action of Emgality (Galcanezumab)
Emgality (galcanezumab) is a humanized IgG4 monoclonal antibody that binds directly to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the CGRP receptor. 1
How It Works
Galcanezumab functions by neutralizing CGRP, a neuropeptide critically implicated in migraine pathophysiology. By binding to the CGRP molecule itself (rather than the receptor), it prevents CGRP from activating its receptor and triggering the cascade of events that lead to migraine attacks 1.
Key Mechanistic Features:
Target specificity: The antibody specifically binds to the CGRP ligand with high affinity, reducing free CGRP concentrations in a dose- and time-dependent manner 2
Site of action: Distribution studies show galcanezumab concentrates primarily in peripheral tissues—particularly the dura mater and trigeminal ganglia (5-11% of plasma levels)—while CNS penetration remains minimal (<0.4% of plasma levels) 3. This peripheral distribution pattern suggests the drug acts primarily at the trigeminovascular system rather than centrally.
Functional effects: Preclinical models demonstrate that galcanezumab robustly reduces trigeminal nociception, decreasing spontaneous neuronal activity by up to 73% and noxious-evoked responses by 38-48% in the trigeminocervical complex 4
Additional Mechanistic Insights
Beyond simple CGRP blockade, emerging evidence suggests galcanezumab may modulate inflammatory pathways. Recent data show treatment transiently reduces both pro-inflammatory cytokines (IFN-γ, IL-1β, TNF-α) and anti-inflammatory cytokines (IL-10) during the first month of therapy 5. This suggests CGRP may influence broader inflammatory mechanisms in migraine pathophysiology.
Clinical positioning: Current guidelines classify galcanezumab and other CGRP monoclonal antibodies as second-line or third-line preventive agents for episodic migraine, recommended after inadequate response to first-line treatments (beta-blockers, valproate, venlafaxine, or amitriptyline) 6. For chronic migraine, CGRP antibodies including galcanezumab are evidence-based options alongside topiramate and onabotulinumtoxinA 7.